Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

NCT01974895 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

316

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: FluLaval® Quadrivalent
BIOLOGICAL: Fluzone®

Sponsor

GlaxoSmithKline